Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Muschitz, C; Fahrleitner-Pammer, A; Huber, J; Preisinger, E; Kudlacek, S; Resch, H.
Update on denosumab in postmenopausal osteoporosis--recent clinical data.
Wien Med Wochenschr. 2012; 162(17-18):374-379 Doi: 10.1007/s10354-012-0116-x
PubMed FullText FullText_MUG


Co-Autor*innen der Med Uni Graz
Fahrleitner-Pammer Astrid

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Denosumab, a fully human monoclonal antibody against the key osteoclastogenic factor RANK ligand, is currently approved for the treatment of postmenopausal osteoporosis. Denosumab differs from bisphosphonates in many aspects, for example, its ability to act in the extracellular compartment and its likelihood to be distributed throughout the skeleton. In contrast, bisphosphonates have to be internalized by osteoclasts and are mainly located across bone surfaces. This could explain why patients with osteoporosis, who are already treated with bisphosphonates, might experience further benefit when switching to denosumab. Head-to-head studies revealed that transition to denosumab resulted in a greater increase of bone mineral density (BMD) and a greater reduction of bone turnover than did continued alendronate. Additional analyses of the phase 3 FREEDOM trial demonstrated that fracture reduction was particularly high in cortical bone, such as the wrist. In addition, denosumab treatment for a 5- and 8-year period showed sustained reduction in fracture risk, increase in BMD and continued to be well tolerated. The 7-year extension study of FREEDOM and a phase 3 trial evaluating denosumab for the treatment of male osteoporosis are still ongoing and will provide supportive data in the near future.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Alendronate - adverse effects
Antibodies, Monoclonal, Humanized - adverse effects
Bone Density - drug effects
Bone Density Conservation Agents - adverse effects
Clinical Trials, Phase III as Topic -
Diphosphonates - therapeutic use
Double-Blind Method -
Drug Substitution -
Female -
Humans -
Long-Term Care -
Middle Aged -
Osteoclasts - drug effects
Osteoporosis, Postmenopausal - drug therapy
Osteoporotic Fractures - prevention & control
RANK Ligand - antagonists & inhibitors
Radius Fractures - prevention & control
Randomized Controlled Trials as Topic -
Wrist Injuries - prevention & control

© Med Uni Graz Impressum